Assessing pain tolerance, balance, and strength in children with sickle cell anemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the relationship between pressure pain tolerance, balance, and muscle strength in children aged 9-14 with sickle cell anemia. It involves measuring pain tolerance using a Digital Pressure Algometer, assessing balance with the HUMAC balance system, and evaluating lower limb muscular strength with a Lafayette hand-held dynamometer. The study includes 80 participants, with half being healthy children and the other half having sickle cell anemia, to understand how these factors affect their physical capabilities. The goal is to inform future guidelines for safe exercise prescriptions for children with this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age range range was 9-14 years old.
* Could follow given instructions.
* Children with Sickle cell anemia were medically stable, and take their medications regularly.
* Children with Sickle cell anemia had experience of chronic pain that lasts more than 6 months.
* All children with Sickle cell anemia have average weight, height, and body mass index based on their age percentiles.
* All normal healthy children did not participating in regular sport activities, particularly including lower limb strengthening.

Exclusion Criteria:

* Defined cardiovascular or respiratory disorders.
* Renal failure.
* Myocardial infarction, mainly within last month.
* Unstable angina.
* Recent thoracoabdominal surgery.
* Thoracic or abdominal aneurysm or current pneumothorax.
* Painful vaso-occlusive crises.
* Muscular contractures, Joints' stiffness, or deformities.
* Neuromuscular problems i.e., myositis or peripheral neuropathy.

Where it's running

• El-Tahrir st.- in front of Ben El-Sarayat, Ad Doqi Al Giza, Giza Governate
  Giza, Egypt Recruiting

Study contacts

• Study coordinator: Mahmoud M Metwaly, MD
• Email: malmanakhly10@gmail.com
• Phone: 0102572862

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Checking measles vaccine response in children with sickle cell disease

  This study tests whether infants and young children with sickle cell disease develop enough protection in the weeks after their measles vaccine.

  Recruiting at 3 sites Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio and 2 other locations · NCT07356050

• Senicapoc for Sickle Cell Disease with Hemolytic Phenotype

  A mid-stage study tests whether daily senicapoc helps people with sickle cell disease who have ongoing red blood cell breakdown and low hemoglobin, despite hydroxyurea, by comparing it to a placebo over 24 weeks.

  Recruiting at 4 sites Phase 2 Biossil Inc. · Toronto, Ontario and 3 other locations · NCT07282210

• Tracking growth, puberty, fertility, and pregnancy in people with sickle cell anemia

  This study will see if taking hydroxyurea changes growth, puberty, fertility, or pregnancy outcomes in people with sickle cell anemia.

  Recruiting at 3 sites Children's Hospital Medical Center, Cincinnati · Santo Domingo and 2 other locations · NCT07116772

• Using alendronate to treat osteonecrosis in adults with sickle cell disease

  This study is testing if a weekly medication called alendronate can help adults with sickle cell disease who have bone pain from osteonecrosis feel better and improve their bone health.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06016634

• Evaluating a single dose of CTX001 for treating transfusion-dependent beta-thalassemia and severe sickle cell disease

  This study is testing a single dose of a new treatment called CTX001 to see if it can help people with transfusion-dependent beta-thalassemia or severe sickle cell disease feel better.

  Recruiting at 6 sites Phase 3 Vertex Pharmaceuticals Incorporated · New York, New York and 5 other locations · NCT05477563

• Haploidentical stem cell transplantation for sickle cell disease

  This study is testing a new type of stem cell transplant for people with sickle cell disease to see if it can cure the disease while causing fewer complications.

  Recruiting at 4 sites Phase 2 University of Regensburg · Vienna and 8 other locations · NCT04201210

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.